<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920686</url>
  </required_header>
  <id_info>
    <org_study_id>NXN-188-203</org_study_id>
    <nct_id>NCT00920686</nct_id>
  </id_info>
  <brief_title>Study of NXN 188 for the Treatment of Migraine With Aura</brief_title>
  <official_title>A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeurAxon Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeurAxon Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NXN-188 Dihydrochloride is being developed as an immediate release oral product for the
      treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects
      with a migraine history of aura.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, double-blind, parallel group, active and placebo-controlled, three
      arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache with
      aura.

      After study eligibility was confirmed, subjects were randomized to NXN-188 600 mg,
      sumatriptan 100 mg, or placebo in a 1:1:1 ratio. Subjects left the clinic to self-administer
      the treatment at home at the onset of moderate to severe headache in a suitable dosing
      environment.

      Treatment was not to exceed 42 days from Randomization. If the subject did not have a
      headache within 42 days of randomization (s)he did not take the study medication and returned
      it to the site. If the subject experienced a qualifying headache (s)he recorded the symptoms
      in a diary, dosed with the study drug, and called the IVRS to record assessments all adverse
      events and to report dosing. If the study drug provided insufficient relief 2 hours post
      dosing (s)he was permitted to use non-triptan rescue medication recommended by the
      investigator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (Hours) to First Use of Rescue Medication</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Relief and Recurrence (Observed Cases)</measure>
    <time_frame>2, 4 and up to 24 hours</time_frame>
    <description>Headache relief is defined as a ≥ 1-point reduction from baseline in Headache Severity Score. The Headache Severity Score is a four-point scale: 0=no pain; 1 = mild pain; 2 = moderate pain; and 3 = severe pain.
Headache recurrence is defined as any subject that experiences headache relief within 4 hours, who did not use rescue medication, and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</measure>
    <time_frame>2 hours</time_frame>
    <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</measure>
    <time_frame>4 hours</time_frame>
    <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</measure>
    <time_frame>24 hours</time_frame>
    <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>NXN-188</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NXN-188, 600 mg, PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sumatriptan succinate 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sumatriptan, 100 mg, PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching, PRN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXN-188</intervention_name>
    <description>NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules</description>
    <arm_group_label>NXN-188</arm_group_label>
    <other_name>NXN-188 dihydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>administered as 3 placebo hard gelatin capsules</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sumatriptan succinate</intervention_name>
    <description>administered in a hard gelatin capsule with 2 capsules of placebo</description>
    <arm_group_label>sumatriptan succinate 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female migraineurs between 18 and 65 years old.

          2. Subjects must have a headache history of migraine with aura as defined by:

               -  Aura consisting of at least one of the following, but no muscle weakness or
                  paralysis:

                    -  Fully reversible visual symptoms

                    -  Fully reversible sensory symptoms

                    -  Fully reversible dysphasia

               -  Aura has at least two of the following characteristics:

                    -  Visual symptoms affecting only one side of the field of vision and/or
                       sensory symptoms affecting only one side of the body

                    -  At least one aura symptom that develops gradually over more than 5 minutes
                       and/or different aura symptoms occur in succession over more than 5 minutes

                    -  Each symptom lasts from 5-60 minutes

               -  Headache begins during the aura or follows aura within 60 minutes

               -  Headache not attributable to another disorder

          3. Migraine pain following aura in at least 75% of occurrences

          4. Headache frequency of at least 1 migraine attack (with or without aura) per month for
             the past 3 months but not more than 8 migraines in any 30 day period. Subjects must
             have at least 1 migraine headache with aura per month

             • Each migraine attack should last at least 4 hours (without treatment) and not longer
             than 72 hours.

          5. At the time of the study migraine, prior to dosing with study medication, the headache
             severity, as judged and documented by the subject, is either moderate or severe (on a
             4-point categorical scale)

          6. Body mass index (BMI) range of 18 to 35

          7. The subject is in general good health.

             • ALT cannot be above 1.5x upper limit of normal; creatinine and urea must be within
             normal limits

          8. Speak, read, and understand English, French, or Spanish sufficiently to understand the
             nature of the study, to provide written informed consent, and complete all study
             assessments

          9. The subject is willing and able to comply with all testing requirements defined in the
             protocol

         10. All females will avoid pregnancy at least 10 days before randomization, and up until 3
             months after dosing.

         11. All subjects/partners must use a double-barrier method of birth control during the
             study and for 3 months after dosing.

        Exclusion Criteria:

          1. A diagnosis of headaches that is not consistent with migraine with aura.

          2. Presence of any risk factors that would preclude the use of triptans:

          3. Known allergy or hypersensitivity to triptans or history of any serious side effect
             with a triptan which would preclude further dosing with a triptan

          4. Presence of any clinically significant condition that would preclude study
             participation, as evaluated by the investigator

          5. Pregnancy or lactation

          6. History of significant neurological, hepatic, renal, endocrine, cardiovascular,
             gastrointestinal, pulmonary, rheumatologic, autoimmune, or metabolic disease

          7. Use of the following if taken for migraine prevention:

               -  Cardiovascular drugs (acceptable if reason for use is for treatment of
                  cardiovascular disease and the subject has been on a stable dose for 3 months)

               -  Valproate, topiramate, cyproheptadine, montelukast, or botulinum toxin.

          8. Use of monoamine oxidase inhibitors within 30 days of randomization

          9. Initiation of therapy with SSRIs or SNRIs for depression or other approved indication
             within 90 days of randomization (subjects on stable dose for &gt;3 months for treatment
             of depression or other approved indication may be included)

         10. Are known to or suspected to be currently abusing alcohol or drugs, or have a history
             (within the past 12 months) of active alcohol or drug abuse

         11. Participation in another drug or biologic study within 30 days of randomization into
             this study or during participation in this study

         12. Subjects who are unable or unwilling, in the opinion of the Investigator, to comply
             with all study procedures and cooperate fully with study center staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Boudreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Notre-Dame Du Chum, Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C. Philip O'Carrroll, MD, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of Southern California, LLC</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Headache Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc.</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head-Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Care Center/Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkind Headache Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mt. PLeasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, Inc.</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <results_first_submitted>May 8, 2013</results_first_submitted>
  <results_first_submitted_qc>July 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2014</results_first_posted>
  <last_update_submitted>July 20, 2014</last_update_submitted>
  <last_update_submitted_qc>July 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>aura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient Screened: 17 June 2009 Last Patient: 17 December 2009</recruitment_details>
      <pre_assignment_details>Subjects meeting eligibility requirements at Screening were randomized at Visit 1 to NXN-188 600 mg, sumatriptan 100 mg or placebo in a 1:1:1 ratio. Randomized subjects were instructed to take study drug when they experienced a mild to moderate migraine headache with aura. Sunbjects not meeting the dosing criteria were discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>3 x 0 mg capsules</description>
        </group>
        <group group_id="P2">
          <title>NXN-188 600 mg</title>
          <description>3 x 200 mg capsules</description>
        </group>
        <group group_id="P3">
          <title>Sumatriptan Succinate 100 mg</title>
          <description>1 x 100 mg, 2 x 0 mg capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug dosing criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>3 x 0 mg capsules</description>
        </group>
        <group group_id="B2">
          <title>NXN-188 600 mg</title>
          <description>3 x 200 mg capsules</description>
        </group>
        <group group_id="B3">
          <title>Sumatriptan Succinate 100 mg</title>
          <description>1 x 100 mg, 2 x 0 mg capsules</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="10.90"/>
                    <measurement group_id="B2" value="41.4" spread="13.02"/>
                    <measurement group_id="B3" value="41.2" spread="12.03"/>
                    <measurement group_id="B4" value="39.9" spread="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.6" spread="16.95"/>
                    <measurement group_id="B2" value="76.3" spread="16.61"/>
                    <measurement group_id="B3" value="74.2" spread="14.50"/>
                    <measurement group_id="B4" value="75.7" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.5" spread="9.01"/>
                    <measurement group_id="B2" value="167.8" spread="8.67"/>
                    <measurement group_id="B3" value="166.3" spread="8.82"/>
                    <measurement group_id="B4" value="167.9" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="4.54"/>
                    <measurement group_id="B2" value="27.0" spread="5.31"/>
                    <measurement group_id="B3" value="26.9" spread="4.48"/>
                    <measurement group_id="B4" value="26.8" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Applicable Aura Symptoms for Qualifying Migraine</title>
          <description>Safety Population - included all subjects who were randomized and dosed with study drug.
Subject may have reported more than one aura symptom.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Flickering lights</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spots</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Vision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pins and needles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphasia (speech disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Migraine</title>
          <description>Subjects are counted once within each type where at least one migraine is recorded.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Without Aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Migraines per month</title>
          <description>Number of Previous Migraines for each subject was based on the total number of migraine entries reported on the Migraine History CRF.</description>
          <units>migraines per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.59"/>
                    <measurement group_id="B2" value="1.5" spread="0.50"/>
                    <measurement group_id="B3" value="1.5" spread="0.50"/>
                    <measurement group_id="B4" value="1.5" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time (Hours) to First Use of Rescue Medication</title>
        <time_frame>24 hours</time_frame>
        <population>The Full Analysis Set included all those subjects randomized who had dosed with study drug and had at least one (1) post study drug administration observation for headache severity. The Efficacy Evaluable Analysis Set, included all subjects with an imputed (LOCF) HSS at both the 2 hour time point and the 4 hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Three capsules containing placebo</description>
          </group>
          <group group_id="O2">
            <title>NXN-188</title>
            <description>600 mg of NXN-188 provided as 3 x 200 mg capsules.</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan Succinate</title>
            <description>100 mg of sumatriptan succinate provided as 1 capsule containing 100 mg of sumatriptan and 2 capsules containing placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time (Hours) to First Use of Rescue Medication</title>
          <population>The Full Analysis Set included all those subjects randomized who had dosed with study drug and had at least one (1) post study drug administration observation for headache severity. The Efficacy Evaluable Analysis Set, included all subjects with an imputed (LOCF) HSS at both the 2 hour time point and the 4 hour time point.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="10.1">The median time to rescue was not estimable by Kaplan-Meier because an insufficient number of subjects took rescue medication in this data set for any dose group.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="6.4">The median time to rescue was not estimable by Kaplan-Meier because an insufficient number of subjects took rescue medication in this data set for any dose group.</measurement>
                    <measurement group_id="O3" value="NA">The median time to rescue was not estimable by Kaplan-Meier because an insufficient number of subjects took rescue medication in this data set for any dose group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6407</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Relief and Recurrence (Observed Cases)</title>
        <description>Headache relief is defined as a ≥ 1-point reduction from baseline in Headache Severity Score. The Headache Severity Score is a four-point scale: 0=no pain; 1 = mild pain; 2 = moderate pain; and 3 = severe pain.
Headache recurrence is defined as any subject that experiences headache relief within 4 hours, who did not use rescue medication, and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration.</description>
        <time_frame>2, 4 and up to 24 hours</time_frame>
        <population>Number of subjects who experienced headache relief within 4 hours</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 x 0 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan Succinate 100 mg</title>
            <description>1 x 100 mg, 2 x 0 mg capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Relief and Recurrence (Observed Cases)</title>
          <description>Headache relief is defined as a ≥ 1-point reduction from baseline in Headache Severity Score. The Headache Severity Score is a four-point scale: 0=no pain; 1 = mild pain; 2 = moderate pain; and 3 = severe pain.
Headache recurrence is defined as any subject that experiences headache relief within 4 hours, who did not use rescue medication, and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration.</description>
          <population>Number of subjects who experienced headache relief within 4 hours</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache Relief - 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6"/>
                    <measurement group_id="O2" value="62.0"/>
                    <measurement group_id="O3" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Relief - 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5"/>
                    <measurement group_id="O2" value="81.1"/>
                    <measurement group_id="O3" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
        <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
        <time_frame>2 hours</time_frame>
        <population>Number of subjects with headache relief at 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 x 0 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan Succinate 100 mg</title>
            <description>1 x 100 mg, 2 x 0 mg capsules</description>
          </group>
        </group_list>
        <measure>
          <title>2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
          <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
          <population>Number of subjects with headache relief at 2 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Headache Relief-Observed Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phonophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Score-Improvement from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
        <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
        <time_frame>4 hours</time_frame>
        <population>Number of subjects with headache relief at 4 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 x 0 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan Succinate 100 mg</title>
            <description>1 x 100 mg, 2 x 0 mg capsules</description>
          </group>
        </group_list>
        <measure>
          <title>4 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
          <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
          <population>Number of subjects with headache relief at 4 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Headache Relief-Observed Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phonophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Score-Improvement from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
        <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
        <time_frame>24 hours</time_frame>
        <population>Number of subjects with headache relief at 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>3 x 0 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Sumatriptan Succinate</title>
            <description>1 x 100 mg, 2 x 0 mg capsules</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea</title>
          <description>Complete headache relief is defined as reduction of headache severity from moderate or severe to absent.
Presence of Photophobia and Phonophobia measured on a 2-point scale: 0 = absent; 1 = present
Nausea was measured on a 4-point scale: 0 = no nausea; 1 = mild nausea; 2 = moderate nausea; 3 = severe nausea</description>
          <population>Number of subjects with headache relief at 24 hours.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Headache Relief-Observed Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phonophobia-Shift from Baseline (present-absent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Score-Improvement from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Eval-Study Medication-(Good/Excellent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected beginning at Randomization until 30 days after study drug administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Three placebo capsules were provided. All capsules were taken at the same time.</description>
        </group>
        <group group_id="E2">
          <title>NXN-188</title>
          <description>600 mg NXN-188. Three capsules each containing 200 mg of NXN-188 were provided. All capsules were taken at the same time.</description>
        </group>
        <group group_id="E3">
          <title>Sumatriptan Succinate</title>
          <description>100 mg sumatriptan. Three capsules, one containing 100 mg sumatriptan succinate and two placebo-containing capsules were provided. All capsules were taken at the same time.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor may request the Investigator or Institution not to publish or disclose information related to the clinical study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Lategan, PhD</name_or_title>
      <organization>NeurAxon, Inc</organization>
      <phone>417 673 6697</phone>
      <email>tlategan@neuraxon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

